The need of standardization and of large clinical studies in an emerging indication of [18F]FDG PET. the autoimmune encephalitis
01 Pubblicazione su rivista
Morbelli S., Arbizu J., Booij J., Chen M. -K., Chetelat G., Cross D. J., Djekidel M., Drzezga A., Ekmekcioglu O., Garibotto V., Hesse S., Ishii K., Saraf L. J., Lammertsma A. A., Law I., Mathews D., Minoshima S., Mosci K., Pagani M., Pappata S., Silverman D. H., Signore A., Van De Giessen E., Villemagne V., Barthel H.
ISSN: 1619-7070
[18F]FDG PET is currently the most commonly used functional imaging method for the in vivo investigation of regional brain metabolism in clinical practice. PET/CT scanners are widely available in Europe, in the US, in Australia, and most of the rest of the world [1] and the clinical role of [18F]FDG brain PET can be regarded as established for a number of diagnostic challenges in Neurology and Psychiatry [2]. In particular, [18F]FDG PET plays a major role in the early and differential diagnosis of neurodegenerative dementias and Parkinsonian syndromes by showing disease-specific patterns of hypometabolism [3].